Clinical Evidence Supporting FDA Clearance of First-of-a-Kind Therapeutic Devices via

the De Novo Pathway Between 2011 and 2019

James L. Johnston, BS¹ Sanket S. Dhruva, MD, MHS^{2.3} Joseph S. Ross, MD, MHS^{4.5.6} Vinay K. Rathi, MD^{7.8}

¹ Yale School of Medicine, New Haven, CT; ² San Francisco Veterans Affairs Medical Center, San Francisco, CA; ³ Department of Medicine, University of California, San Francisco School of Medicine, San Francisco, CA; ⁴ Center for Outcomes Research and Evaluation (CORE), Yale-New Haven Hospital, New Haven, CT; ⁵ Department of Health Policy and Management, Yale School of Public Health, New Haven, CT; ⁶ Section of General Internal Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT; ⁷ Department of Otolaryngology -Head and Neck Surgery, Massachusetts Eye and Ear Infirmary, Boston, MA; ⁸ Harvard Business School, Boston, MA

Correspondence to:

Vinay K. Rathi, MD Department of Otolaryngology - Head and Neck Surgery, Massachusetts Eye and Ear Infirmary, 243 Charles Street, Boston, MA 02114 Email: vinay_rathi@meei.harvard.edu Phone: 617-573-3653

Word count: 3134 References: 27 Tables: 5 Figures: 1

KEY POINTS

Question: What is the strength of premarket clinical evidence supporting FDA clearance of firstof-a-kind therapeutic devices via the De Novo review pathway?

Findings: In this retrospective cross-sectional analysis of 63 devices, 43% were cleared without supporting premarket pivotal studies or based on pivotal studies that failed to meet at least one primary effectiveness endpoint. The FDA rarely required postmarket studies of therapeutic De Novo devices, which often served as the basis for new models and competitor products subsequently cleared via the 510(k) process.

Meaning: The FDA often clears first-of-a-kind therapeutic devices via the De Novo pathway despite limited clinical evidence of effectiveness.

ABSTRACT

Importance: In recent years, the US Food and Drug Administration (FDA) and manufacturers have increasingly sought to expedite patient access to first-of-a-kind devices via the De Novo premarket review pathway. Understanding the strength of clinical evidence supporting FDA clearance through this pathway can help guide clinical adoption of novel devices and ongoing regulatory development of the postmarket surveillance infrastructure.

Objective: Our primary objective was to characterize the strength of clinical evidence supporting FDA clearance of therapeutic De Novo devices. Key secondary objectives were 1) characterization of FDA post-marketing requirements for De Novo devices and 2) study of the use of these devices as the basis for devices subsequently cleared via the 510(k) process.

Design: Retrospective cross-sectional analysis

Setting: Publicly available online FDA databases, including the De Novo database, the 510(k) clearance database, the 522 Post Market Surveillance database, and the Recalls of Medical Devices database

Participants: All moderate-risk therapeutic devices cleared via the De Novo pathway between January 1, 2011, and December 31, 2019.

Main Outcome Measures: (1) proportion of De Novo devices cleared based on evidence from a pivotal clinical study, (2) proportion of pivotal study primary effectiveness endpoints that were met, (3) proportion of De Novo devices subject to FDA-required postmarket studies, and (4) proportion of De Novo devices serving as the basis for at least one subsequently cleared 510(k) device (i.e., new models or competitor products).

Results: There were 63 (of 65; 96.9%) moderate-risk therapeutic devices cleared by FDA via the De Novo pathway between 2011 and 2019 for which decision summary documentation was

publicly available. Of the 63 devices, 51 (81.0%) were supported by pivotal clinical studies (n=54 studies); the remainder (n=12; 19.0%) were not supported by a pivotal clinical study. The majority of pivotal studies were randomized (57.4%), multi-armed (61.1%), and used an active (25.9%) or sham (35.2%) comparator arm; 17 (31.5%) failed to meet at least one primary effectiveness endpoint. Among the 63 devices cleared via the De Novo pathway, one (1.6%) was subject to an FDA-required posttmarket study and 32 (47.8%) served as a predicate device for new models or competitor devices subsequently cleared through the 510(k) process.

Conclusions: Between 2011 and 2019, the FDA cleared the majority of first-of-a-kind moderaterisk therapeutic devices via the De Novo pathway based on premarket evidence from pivotal clinical studies. However, 43% of devices were cleared without clinical evidence from pivotal studies or based on pivotal studies that failed to meet at least one primary effectiveness endpoint. The FDA rarely required postmarket studies of these devices, which often served as the basis for new models and competitor products subsequently cleared via the 510(k) process.

INTRODUCTION

Under the Medical Device Regulation Act of 1976,¹ the US Food and Drug Administration (FDA) regulates medical devices using a three-tiered risk classification system: class I (low-risk devices, such as bandages), class II (moderate-risk devices, such as glucometers), and class III devices (high-risk devices, such as prosthetic heart valves). Approximately 90% of devices subject to FDA premarket review are classified as moderaterisk.² Moderate-risk devices are primarily regulated through the 510(k) pathway, which requires manufacturers to demonstrate their device is "substantially equivalent" in intended use and technological specifications (with allowable exceptions) to at least one previously FDA-cleared device, known as a "predicate device."³ Fewer than 10% of 510(k) devices are cleared based on supporting premarket clinical evidence; the safety and effectiveness of these devices is presumed based on the evaluation of the predicate device.

The 510(k) pathway was not designed to regulate first-of-a-kind devices; as a result, the FDA was historically required to automatically designate all novel technologies as high-risk, even for devices that presumably conferred lower levels of risk to patients. These technologies were subject to regulation via the Premarket Approval pathway for high-risk devices, which requires clinical evidence for approval and is therefore the longest and most costly route to market. In an effort to reduce barriers to technological innovation and patient access, US Congress established the De Novo pathway under the Food and Drug Administration Modernization Act of 1997.⁴ The De Novo pathway permits manufacturers to establish and market first-of-a-kind low- or moderate risk devices, which may serve as predicates supporting clearance of subsequent 510(k) devices.

Device manufacturers can apply for device clearance via the De Novo pathway following FDA denial of preceding 510(k) applications due to lack of substantial equivalence or (as of 2012) directly when devices have no potential predicates. De Novo pathway applications require several key components, including the recommended risk-classification for the device, the probable benefits and risks accompanying device use, and non-clinical data such as bench performance testing. If non-clinical studies are deemed insufficient to provide reasonable assurance of device safety and effectiveness, the FDA requires clinical data for clearance.⁵

The De Novo pathway has served as a path to market for a variety of devices, such as the single-lead electrocardiogram feature of the Apple[©] Watch and treatments (e.g., embolization and high intensity therapeutic ultrasound devices) for benign prostatic hyperplasia.⁵ In recent years, manufacturers have increasingly sought to market first-of-a-kind devices via the De Novo pathway. Whereas the FDA cleared 65 devices via the De Novo pathway between 1997 and 2012, the agency cleared 165 devices through this pathway between 2013 and 2018.⁶ The FDA anticipates that the importance of the De Novo pathway will continue to grow as the agency seeks to expedite patient access to novel devices relative to international markets.⁶

Given the increasing use of this pathway for novel medical devices, patients, physicians, and policymakers should understand the evidence supporting De Novo clearance. This evidence has important implications for clinical practice, as premarket studies inform both the clinical adoption of De Novo devices as well as subsequent FDA regulation of new models and competitor products, including the need for postmarket surveillance. We therefore sought to systematically characterize the premarket pivotal clinical studies supporting FDA clearance of therapeutic devices cleared via the De Novo Pathway and FDA postmarket experience with these devices.

METHODS

Device Cohort

We conducted a retrospective cross-sectional analysis of therapeutic devices cleared through the De Novo pathway between January 1, 2011, and December 31, 2019, using the FDA De Novo database (**Figure 1**).⁷ We restricted our analysis to devices cleared after 2010 because the FDA began releasing documents summarizing the premarket evidence supporting clearance during this year; devices without publicly available summary documents were excluded from analysis.⁸ We chose to focus on therapeutic devices because these technologies are typically evaluated based on clinical safety and effectiveness data rather than concordance with reference standards (as is often the case for diagnostic devices).

Using FDA-designed product codes,⁹ we classified each De Novo device as either therapeutic or non-therapeutic (e.g., diagnostic tests or procedural equipment). For each therapeutic device, we determined the clearance year, FDA-designated medical specialty, and whether the manufacturer submitted the marketing application directly via the De Novo pathway or following a denied 510(k) application. We additionally extracted whether the FDA classified the device as implantable (yes/no) and life-sustaining (yes/no).

Premarket Study Evidence: Pivotal Studies

There are two types of premarket clinical studies for medical devices – non-pivotal studies (e.g., small-scale feasibility studies) and pivotal studies, which generally serve as the primary basis for device clearance.¹⁰ Using previously described methods, we reviewed publicly available documents within the FDA De Novo database to identify all pivotal clinical studies

supporting clearance of devices in our sample.¹¹ We categorized each pivotal study by the following characteristics: total number of patients enrolled, total number of patients enrolled in treatment device group, comparator type (active/sham/pre-post comparison/historical/none), randomization (yes/no), blinding (yes/no), study arms (single/multiple), study location (US/Outside US/mixed), number of study centers (single-center/multi-center), and duration of longest primary effectiveness endpoint follow-up. For each study, we categorized all primary endpoints by the following characteristics: outcome type (safety/effectiveness), effectiveness endpoint type (clinical outcome/clinical scale/surrogate marker), and endpoint met (yes/no/not specified).¹¹

Postmarket Experience: Postmarketing Requirements, Recalls, and Subsequent 510(k) Devices

We characterized FDA postmarket experience with devices in our sample by several means. First, we identified all FDA-required postmarket studies of these devices. FDA-required postmarket studies are intended to complement premarket understanding of device benefits and risks. To identify postmarket study requirements, we queried the 522 Studies database on March 22, 2020 by device application number.¹² The FDA may order 522 Studies for moderate- or high-risk devices when device failure would be reasonably likely to cause significant health problems. We categorized each required postmarket study by purpose (evaluation of safety/evaluation of effectiveness).

Second, we extracted the recall history of the De Novo devices in our sample using the FDA Recalls of Medical Devices database. We queried this database on March 1, 2020, using device application numbers to determine if a device was recalled and, if applicable, the FDA-designated recall class (Class I – highest risk/Class II – moderate risk/Class III – low risk).¹³

Third, we identified all 510(k) clearances of new models and competitor products based on De Novo devices in our sample. For each device, we queried the FDA 510(k) database on March 13, 2020,¹⁴ using FDA-designated product codes. We collected the dates of first clearance for: (1) new models marketed by De Novo manufacturers and; (2) first competitor devices marketed by other manufacturers. We also collected the number of 510(k) clearances for each device and market lifespan (in days) as of March 13, 2020.

Statistical Analysis

We used descriptive statistics to characterize therapeutic De Novo devices, premarket pivotal studies and primary endpoints, postmarket study requirements, and 510(k) device lineages. For each De Novo device linked to a subsequent 510(k) device, we calculated median time to first 510(k) device, median time to first competitor device clearance, and median number of subsequent 510(k) clearances per year. All analyses were performed in Microsoft Excel (Microsoft Corporation; Redmond, Washington, USA).

RESULTS

Device Cohort

Between January 1, 2011, and December 31, 2019, the FDA cleared 210 first-of-a-kind devices through the De Novo pathway (**Figure 1**). Among these 210 devices, 68 (32.4%) were therapeutic. Of those 68 devices, 65 (95.6%) were FDA-classified as moderate-risk. Of these 65 devices, decision summary documents were available in the FDA's De Novo database for 63 (96.9%).

Among these 63 first-of-a-kind moderate-risk therapeutic devices, the FDA classified zero (0.0%) as life-sustaining and 10 (15.9%) as implantable (**Table 1**). The most commonly represented medical specialties were neurology (18 of 63: 28.6%), gastroenterology and urology (13 of 63: 20.6%), and general and plastic surgery (10 of 63: 15.9%). Nearly three-quarters (48 of 63: 76.2%) were cleared through the direct De Novo pathway, with the remainder (15 of 63: 23.8%) cleared following FDA denial of a preceding 510(k) application.

Premarket Study Evidence: Pivotal Studies

Among the 63 moderate-risk, therapeutic medical devices, 12 (19.0%) devices were not supported by a pivotal study; instead, these devices were cleared on the basis of non-pivotal (feasibility) studies, literature review of similar devices, or postmarket data from other localities such as the European Union (**Table 2**). Examples of De Novo devices that were not supported by premarket pivotal studies include a transesophageal core temperature cooling device, a cerebrospinal fluid drainage system for patients with post-operative neurologic deficits, and a fertility planning software.

In total, we identified 54 pivotal studies supporting the clearance of 51 (of 63; 81.0%) devices (**Table 3**). Among pivotal studies, 31 (57.4%) were randomized, 23 (42.6%) were blinded, 41 (75.9%) were multi-center, and 33 (61.1%) were multi-armed. Among multi-armed studies, 14 (42.4%) used an active comparator and 19 (57.6%) used a sham comparator. Among single-armed studies, 8 (38.1%) used participant pre/post comparisons, 11 (52.4%) used no comparator, and 2 (9.5%) used a historical comparator (**Table 3**). Median study enrollment for all pivotal studies was 112.5 patients (IQR: 73.5-187). For multi-armed pivotal studies, median

study enrollment was 150 (IQR: 100-206) patients and the median treatment group enrollment was 89 (IQR: 49-118.5) patients.

We identified 60 primary effectiveness endpoints within these 54 pivotal studies; FDA documents specified no primary endpoint for five studies supporting five devices (**Table 4**). Of those 60 primary effectiveness endpoints, 36 (60.0%) evaluated clinical outcomes (e.g., reduction in hemhorrhoids rate during child delivery), 17 (28.3%) were clinical scales (e.g., reduction in Reflux Symptom Index), and 7 (11.7%) were surrogate markers of disease (e.g., increase in number of active Meibomian glands). The median duration of longest primary effectiveness endpoint follow up was 1.0 months (IQR: 0.0-3.0 months) for non-implantable devices and 9.5 months (IQR: 3.5-12.0 months) for implantable devices. All 27 (100.0%) primary safety endpoints were met.

Among primary effectiveness endpoints, 66.7% (n=40) were met, 30.0% (n=18) were not met, and 3.3% (n=2) did not have their success/failure disclosed within FDA documents. In total, 17 (of 54; 31.5%) pivotal studies supporting 15 (of 63; 23.8%) devices failed at least one primary effectiveness endpoint. FDA reasons for clearing these devices included the success of a coprimary endpoint, post hoc analyses suggesting benefit, and lower risk profile than therapeutic alternatives (e.g., pharmaceutical agents) (**Table 5**). Examples of De Novo devices that were supported by pivotal studies that failed primary effectiveness endpoints include a transcutaneous vagal nerve stimulator for migraine prophylaxis, treatment for urinary incontence, and embolic protection system used during transcather aortic valve replacement procedures.

Postmarket Experience: Postmarketing Requirements and Recalls

Between 2011 and 2019, the FDA required a postmarket study for one (of 63; 1.6%) therapeutic De Novo device. This device was a powered exoskeleton indicated to help patients with weakened or paralyzed limbs ambulate. This study was intended to examine the long-term safety of the device because failure could result in fall-related injuries. This device was subsequently recalled due to postmarket reports of patients suffering injury to their tibias and fibulas.

The vast majority (n=57 of 63; 90.5%) of De Novo devices were not recalled. Six devices (of 63: 9.5%) underwent class II (i.e., moderate-risk) recalls. Three devices were recalled due to shipping problems or improper device labeling. One device - an endoscopic hemostat for gastrointestinal bleeding - was recalled due to a malfunction with the potential to delay hemostasis. Two devices - a robotic system for benign prostatic hyperplasia and a localized heating device for chronic eyelid cysts - were recalled due to component issues that resulted in device failures.

Postmarket Experience: Subsequent 510(k) Devices

Thirty-two (of 63: 50.8%) moderate-risk therapeutic De Novo devices served as the predicate for at least one device subsequently cleared via the 510(k) process (i.e., 510[k] devices). Among these De Novo devices, the median number of 510(k) devices was 2.5 (IQR: 1-5) and the median number of 510(k) devices per year was 0.74 (IQR: 0.54-1.14). The median time from initial De Novo clearance to first 510(k) device clearance was 202 (IQR: 159-302) days.

Sixteen (of 63; 25.4%) De Novo devices served as the basis for at least one device from a competing manufacturer. For these 16 devices, the median time from initial De Novo clearance

to first competing manufacturer 510(k) device was 364 (IQR: 184.5-632.0) days. The competitor product served as the first 510(k) device for the majority (n=11 of 16; 68.8%) of these devices.

Eleven devices served as the basis for 510(k) devices marketed by both the De Novo device manufacturer and and a competing device manufacturer. For these devices, the median time to first competing manufacturer 510(k) device was 426 (IQR: 161.5-678.5) days after De Novo clearance and the median time to first De Novo manufacturer 510(k) device was 439 (IQR: 220-552) days.

DISCUSSION

We found substantial variation in the strength of evidence supporting first-of-a-kind therapeutic medical devices cleared via the De Novo pathway between 2011 and 2019. The majority of devices were cleared based on evidence from pivotal clinical studies. Among pivotal studies, most were randomized, multi-armed studies with an active or sham comparator. However, 43% of devices were not evaluated through pivotal studies or supported by pivotal studies with at least one failed primary effectiveness endpoint

Despite these potential limitations in premarket evidence, the FDA required only one device – a powered exoskeleton – to undergo postmarket study. This device was subsequently recalled after causing lower extremity injuries. Nonetheless, overall few devices were recalled. These safety findings are reassuring, as nearly half of De Novo devices in our cohort served as a predicate device for a subsequent 510(k) device, including nearly a quarter that served as a predicate for a competitor product.

To our knowledge, our study is the first to systematically review medical devices cleared via the FDA De Novo pathway. In contrast to the oft scrutinized 510(k) process,^{2,15} the De Novo

pathway typically requires manufacturers to submit clinical evidence of device safety and effectiveness. When pivotal studies are not required, the FDA often considers alternative clinical data sources, although these may be limited by biases due to selective publication or the challenges of detecting postmarket safety signals.^{16,17} When pivotal studies are required, premarket clinical evidence is generally less rigorous than that required for approval of high-risk devices via the Premarket Approval pathway.^{11,18} Less stringent evidentiary requirements are consistent with the original FDA aim of reducing barriers to market for these comparatively lower-risk devices, but have significant implications for patients and clinicians.

Much variability in the strength of premarket evidence supporting De Novo devices may be due to the diverse range of regulated technologies and indications for use. For instance, the evidentiary bar for a software based weight management aid might be reasonably lower than that for a balloon valvuloplasty catheter for treating aortic stenosis; both devices were cleared via the De Novo pathway. However, our findings reveal that the FDA often exercises regulatory disecretion when devices fail to acheive primary effectiveness endpoints. For such devices, the FDA determines probable benefit based on post-hoc analyses, alternative clinical data sources, and comparison to therapeutic alternatives. As a result, the analyses supporting these determinations may suffer from selection bias, inadequate statistical power, or other potential limitations.^{19,20}

Though we found few recalls of De Novo devices, patients, physicians, and payors would benefit from more definitive evidence of device effectiveness. For example, in June 2017, the FDA cleared a cerebral embolic protection device indicated for use during transcatheter aortic valve replacement (TAVR) via the De Novo pathway, despite the fact that the supporting premarket pivotal study failed to meet its primary endpoint (reduction in new lesion volume

within protected brain territories) by one of two preset criterion. The Centers for Medicare and Medicaid (CMS) services subsequently authorized supplemental payment to facilitate device utilization.^{21,22} Recent study of postmarket experience reveals that the device was rapidly adopted into clinical practice, but did not result in significant reduction in post-TAVR stroke or transient ischemic attack.^{21,23} This saga illustrates the need for more rigorous evidentiary standards, which could help minimize clinical opportunity costs and wasteful healthcare spending that result from the adoption of ineffective devices.

De Novo device manufacturers may be reluctant to invest in more rigorous clinical studies under the current regulatory framework for moderate-risk devices. At present, these manufacturers are usually required to conduct potentially uncertain, costly, or time-intensive studies in order to obtain FDA clearance. In contrast, competing manufacturers are often able to market similar devices within a year of De Novo clearance via the 510(k) process, which does not usually require premarket clinical evidence for clearance. To incentivize manufacturers to generate stronger evidence, the FDA could further collaborate with the Centers for Medicare and Medicaid Services (CMS) to align market clearance with payment policy. For example, the FDA and CMS could expand utilization of collaborative parallel premarket review programs to help expedite coverage for devices supported by compelling pivotal clinical data.^{24,25}

The FDA and CMS could additionally leverage real-world data to evaluate these devices, which were largely cleared without comparative outcomes data. Key stakeholders in the medical device ecosystem – such as the FDA, payors, and manufacturers – are now developing the National Evaluation System for Health Technology (NEST) to enable timely real-world evidence generation to fill this gap.²⁶ For example, NEST has funded a randomized clinical study of the effect of the Apple Watch electrocardiogram and irregular rhythm notification features (both

cleared via the De Novo pathway in 2018) on patient-reported outcomes and clinical utilization (of note, this study is being conducted by SSD and JSR). More expeditious integration of Unique Device Identifiers into electronic data sources, particularly electronic health records and claims, would also facilitate real-world data based evaluations of De Novo devices.^{17,27} The European-based Institute for Quality and Efficiency in Healthcare and National Institute for Health and Care Excellence provide a model for the US to use real-world data to make recommendations that guide clinical practice. Data sharing and collaboration with such institutes could additionally strengthen patient protections against ineffective, unsafe, and low-value devices.

Our study has several limitations. First, we restricted analysis to therapeutic devices and our findings may therefore not be generalizable to all devices cleared via the De Novo pathway. Second, our analysis was cross-sectional. It is possible that additional postmarket studies will be required, more recalls will occur, and more 510(k) devices will be cleared for the devices in our sample. Third, our study is limited by the quality and availability of information within FDA review documents. Inaccuracies or omissions within these documents may have influenced our results.

In conclusion, the De Novo pathway has served as an increasingly important path to market for first-of-a-kind therapeutic devices. These devices rapidly serve as the basis for new models and competitor products. Although experience to date suggests that De Novo devices are largely safe, important questions about device effectiveness remain unanswered. Enhanced postmarket surveillance may enable the FDA to best utilize this pathway in the service of patients moving forward.

Acknowledgements

VKR and JSR led study conception and design. JLJ contributed to study design and led drafting the manuscript, data acquisition, and analysis. The primary data sources were publicly available FDA documents. SSD, JSR, and VKR are subject matter experts in the regulation of medical devices. SSD and JSR have additionally received grant funding from the FDA and the Medical Devices Innovation Consortium, through the National Evaluation System for Health Technology, to pioneer methods of medical device postmarket surveillance and evaluation. JSR and VKR provided JLJ with supervision. All authors revised the manuscript for critically important content. VKR is the guarantor.

Mr. Johnston has received support from the FDA through the Yale-Mayo Clinic Center for Excellence in Regulatory Science and Innovation (CERSI) program. Dr. Dhruva currently receives research support through the National Institute of Health (K12HL138046) and the Greenwall Foundation. He also reports receiving travel support from the Food & Drug Administration and the National Evaluation System for health Technology Coordinating Center (NESTcc). In the past 36 months, Dr. Ross received research support through Yale University from Medtronic, Inc. and the Food and Drug Administration (FDA) to develop methods for postmarket surveillance of medical devices (U01FD004585), from the Centers of Medicare and Medicaid Services (CMS) to develop and maintain performance measures that are used for public reporting (HHSM-500-2013-13018I), and from the Blue Cross Blue Shield Association to better understand medical technology evaluation; Dr. Ross currently receives research support through Yale University from Johnson and Johnson to develop methods of clinical trial data sharing, from the Food and Drug Administration to establish Yale-Mayo Clinic Center for Excellence in Regulatory Science and Innovation (CERSI) program (U01FD005938), from the Medical Device Innovation Consortium as part of the National Evaluation System for Health Technology Coordinating Center (NESTcc), from the Agency for Healthcare Research and Quality (R01HS022882), from the National Heart, Lung and Blood Institute of the National Institutes of Health (NIH) (R01HS025164, R01HL144644), and from the Laura and John Arnold Foundation to establish the Good Pharma Scorecard at Bioethics International and to establish the Collaboration for Research Integrity and Transparency (CRIT) at Yale. Dr. Rathi has no conflicts of interest or funding to disclose.

References

- 1. *Medical Device Amendments of 1976.*; 1976. Accessed April 22, 2020. https://www.govinfo.gov/content/pkg/STATUTE-90/pdf/STATUTE-90-Pg539.pdf
- 2. Institute of Medicine. Medical devices and the public's health: the FDA 510(k) clearance process at 35 years. Published online 2011.
- 3. US Food and Drug Administration. The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]. Published online July 28, 2014:42.
- 4. *Food and Drug Administration Modernization Act of 1997*.; 1997. Accessed April 22, 2020. https://www.govinfo.gov/content/pkg/PLAW-105publ115/pdf/PLAW-105publ115.pdf
- 5. US Food and Drug Administration. De Novo Classification Request. FDA. Published November 20, 2019. Accessed April 22, 2020. http://www.fda.gov/medicaldevices/premarket-submissions/de-novo-classification-request
- FDA's De Novo Program Gains Momentum | RAPS. Accessed April 22, 2020. https://www.raps.org/news-and-articles/news-articles/2019/4/fdas-de-novo-program-gainsmomentum
- 7. Device Classification under Section 513(f)(2)(de novo). Accessed October 9, 2019. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/denovo.cfm
- 8. Center for Devices and Radiological Health. Evaluation of Automatic Class III Designation (De Novo) Summaries. *FDA*. Published online February 26, 2020. Accessed April 22, 2020. http://www.fda.gov/about-fda/cdrh-transparency/evaluation-automatic-class-iii-designation-de-novo-summaries
- 9. Product Classification. Accessed April 22, 2020. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm
- US Department of Health and Human Services. Design Considerations for Pivotal Clinical Investigations for Medical Devices: Design Considerations for Pivotal Clinical Investigations for Medical Devices. Published online November 7, 2013. Accessed April 22, 2020. https://www.fda.gov/media/87363/download
- Rathi VK, Krumholz HM, Masoudi FA, Ross JS. Characteristics of Clinical Studies Conducted Over the Total Product Life Cycle of High-Risk Therapeutic Medical Devices Receiving FDA Premarket Approval in 2010 and 2011. *JAMA*. 2015;314(6):604-612. doi:10.1001/jama.2015.8761
- 12. 522 Postmarket Surveillance Studies. Accessed April 22, 2020. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pss.cfm?s=t
- 13. Medical Device Recalls. Accessed April 22, 2020. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRES/res.cfm

- 14. 510(k) Premarket Notification. Accessed April 22, 2020. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm
- 15. Ross JS, Kesselheim AS. FDA Policy and Cardiovascular Medicine. *Circulation*. 2015;132(12):1136-1145. doi:10.1161/CIRCULATIONAHA.114.010295
- 16. Chang L, Dhruva SS, Chu J, Bero LA, Redberg RF. Selective reporting in trials of high risk cardiovascular devices: cross sectional comparison between premarket approval summaries and published reports. *BMJ*. 2015;350:h2613. doi:10.1136/bmj.h2613
- Rising J, Moscovitch B. The Food and Drug Administration's Unique Device Identification System: Better Postmarket Data on the Safety and Effectiveness of Medical Devices. JAMA Intern Med. 2014;174(11):1719-1720. doi:10.1001/jamainternmed.2014.4195
- Jones LC, Dhruva SS, Redberg RF. Assessment of Clinical Trial Evidence for High-Risk Cardiovascular Devices Approved Under the Food and Drug Administration Priority Review Program. *JAMA Intern Med.* 2018;178(10):1418-1420. doi:10.1001/jamainternmed.2018.3649
- Razavi M, Glasziou P, Klocksieben FA, Ioannidis JPA, Chalmers I, Djulbegovic B. US Food and Drug Administration Approvals of Drugs and Devices Based on Nonrandomized Clinical Trials: A Systematic Review and Meta-analysis. *JAMA Netw Open*. 2019;2(9):e1911111-e1911111. doi:10.1001/jamanetworkopen.2019.11111
- 20. Stefansdottir G, Zoungas S, Chalmers J, et al. The post hoc use of randomised controlled trials to explore drug associated cancer outcomes: methodological challenges. *Curr Drug Saf.* 2013;8(5):371-378. doi:10.2174/15748863113086660070
- Khera R, Girotra S. Cerebral Embolic Protection Devices in Transcatheter Aortic Valve Replacement—Effective in Stroke Prevention? *JAMA Intern Med.* Published online February 24, 2020. doi:10.1001/jamainternmed.2019.6763
- 22. Judson TJ, Dhruva SS, Redberg RF. Evaluation of technologies approved for supplemental payments in the United States. *BMJ*. 2019;365:12190. doi:10.1136/bmj.12190
- 23. Alkhouli M, Alqahtani F, Harris AH, Hohmann SF, Rihal CS. Early Experience With Cerebral Embolic Protection During Transcatheter Aortic Valve Replacement in the United States. *JAMA Intern Med.* Published online April 22, 2020. doi:10.1001/jamainternmed.2019.6767
- 24. Program for Parallel Review of Medical Devices. Federal Register. Published October 24, 2016. Accessed April 22, 2020. https://www.federalregister.gov/documents/2016/10/24/2016-25659/program-for-parallel-review-of-medical-devices
- 25. Roginiel AC, Dhruva SS, Ross JS. Evidence supporting FDA approval and CMS national coverage determinations for novel medical products, 2005 through 2016: A cross-sectional study. *Medicine (Baltimore)*. 2018;97(40):e12715. doi:10.1097/MD.000000000012715

- 26. Shuren J, Califf RM. Need for a National Evaluation System for Health Technology. *JAMA*. 2016;316(11):1153-1154. doi:10.1001/jama.2016.8708
- 27. Dhruva SS, Ross JS, Schulz WL, Krumholz HM. Fulfilling the Promise of Unique Device Identifiers. *Ann Intern Med.* 2018;169(3):183-185. doi:10.7326/M18-0526

TABLES

Table 1. First-of-a-kind moderate-risk therapeutic devices cleared by the US Food and Drug Administration through the De Novo Pathway Between 2011 and 2019

	No. (%)	
	(n = 63)	
Approval Year		
2011-2014	20 (31.7)	
2015-2019	43 (68.3)	
Application Type		
Direct De Novo	48 (76.2)	
Post 510(k) Denial	15 (23.8)	
Specialty		
Neurology	18 (28.6)	
Gastroenterology and Urology	13 (20.6)	
General & Plastic Surgery	10 (15.9)	
Otolaryngology	5 (7.9)	
Ophthalmology	4 (6.3)	
Anesthesiology	4 (6.3)	
Cardiovascular	3 (4.8)	
Other	6 (9.5)	
Review Type ^a		
Standard	62 (98.4)	
Expedited	1 (1.6)	
Implantable		
Yes	10 (15.9)	
No	53 (84.1)	
Life Sustaining		
Yes	0 (0)	
No	63 (100)	
FDA Required Postmarket Study		
Yes	1 (1.6)	
No	62 (98.4)	
Highest Recall Class		
Class I	0	
Class II	6 (9.5)	
Class III	0	

No Recall	57 (90.5)

^aExpedited indicates review via the FDA Priority Review Program, which was intended to

facilitate patient access to therapies addressing unmet medical needs in the treatment of serious

or life-threatening conditions

Table 2. Clinical Evidence Supporting De Novo devices not supported by a premarket pivotal study

pplication umber	Device Manufacturer	Device Name	Clearance Date	Device Specialty	FDA ^a Cleared Clinical Indication	Clinical Evidence Submitted
EN180058	Tandem Diabetes Care, Inc.	t:slim X2 insulin pump with interoperable technology	2/14/2019	Clinical Chemistry	Subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin.	No clinical data included in decision summary
EN180013	KCI USA, Inc.	Prevena 125 and Prevena Plus 125 Therapy Units	4/19/2019	General & Plastic Surgery	Aid in reducing the incidence of post-operative seroma and – in high-risk patients – the risk of superficial surgical site infections	Systematic review and meta-analysis of 16 clinical studies evaluating the device, including 2 previously unpublished manufacturer-sponsored trials.
EN170052	Natural Cycles Nordic AB	Natural Cycles	8/10/2018	Obstetrics/ Gynecology	Fertility monitoring software for women > 18 years to help plan or prevent pregnancy	Real-world postmarket data from 37 countries outside the United States
EN170044	Thornhill Research, Inc.	ClearMate	3/14/2019	Anesthesiology	Adjunctive treatment to be used by emergency department clinicians for patients suffering from carbon monoxide poisoning.	- Literature review of 5 published studies evaluating the device. - European study evaluating device for different indication used to support device safety
EN170015	Wilson-Cook Medical, Inc	Hemospray Endoscopic Hemostat	5/7/2018	General & Plastic Surgery	Hemostasis of non-variceal gastrointestinal bleeding.	 One pilot premarket study Two postmarket studies outside the United States
EN160040	Biosphere Medical S.A.	Embosphere Microspheres	6/21/2017	Gastroenterology & Urology	Embolization of arteriovenous malformations, hypervascular tumors, including symptomatic uterine fibroids, and prostatic arteries for symptomatic benign prostatic hyperplasia.	 Review of literature supporting device use for intended indication. Partial results from 3 ongoing phase II trials Database from outside the United States (400+ patients)
EN140018	Advanced Cooling Therapy, LLC	Esophageal Cooling Device	6/23/2015	Cardiovascular	1. Control patient temperature control patient temperature, and 2. Provide gastric decompression and suctioning	Outside the United States postmarket clinical data from 16 patients
EN130016	Revmedx, Inc.	XSTAT	4/3/2014	General & Plastic Surgery	Temporary (maximum 4 hours) control of bleeding from junctional wounds in the groin or axilla not amenable to tourniquet application in adults and adolescents. Intended for battlefield use.	No clinical data

EN120017	Medtronic Neurosurgery	Medtronic DUET External Drainage and Monitoring System	8/22/2014	Neurology	Temporary drainage and monitoring of cerebrospinal fluid (CSF) flow from the lumbar subarachnoid space in:	Review of 5 published studies evaluating CSF draining apparatuses with similar characteristics to the device (n=5) for device indications
					1. Patients undergoing open descending thoracic aortic aneurysm (open TAA) or open descending thoraco-abdominal aortic aneurysm (open TAAA) repair surgery.	
					2. Patients post TAA/TAAA repair that become symptomatic with neurological deficit such as paraplegia.	
EN100025	Office Research in Clinical Amplification	Widexlink in Clear Series Hearing Aids	3/31/2011	Ear Nose Throat	Auditory amplification for individuals with a full range of hearing loss severity (from slight (16 to 25 dB HL) to profound (90+ dB HL)) and all hearing loss configurations.	FDA-requested pilot study (n=12 patients)
EN080015	Numed, Inc.	Nucleus-X PTV Catheter	6/11/2012	Cardiovascular	Balloon aortic valvuloplasty for the treatment of aortic valve stenosis.	Review of literature (n=3 studies) on worldwide experience with balloon aortic valvuloplasty, including studies evaluating the Nucleus family of catheters
EN170086	Allergan	TrueTear Intranasal Tear Neurostimulator	5/17/2018	Ophthalmology	Provides temporary increase in tear production during neurostimulation to improve dry eye symptoms in adult patients with severe dry eye symptoms.	De Novo clearance was for expanded indications from another De Novo device in the analyzed cohort. Clearance was supported by additional analysis of pivotal trials supporting first De Novo device, evaluating device effectiveness at symptom relief, but no new pivotal trials supported new De Novo clearance

^aFDA denotes the US Food and Drug Administration

Table 3. Characteristics of Pivotal Studies Supporting US Food and Drug Administration
Clearance of De Novo Classification Therapeutic Medical Devices Between 2011 and 2019

	Pivotal Studies
	(n = 54)
No. Pivotal Studies per Device, Median (IQR)	1.0 (1.0-1.0)
Total Enrollment, Median (IQR)	112.5 (73.5-187)
Treatment Group Enrollment (IQR)	89 (49-118.5)
Study Arms	
Multi-Armed	33 (61.1%)
Single Armed	21 (38.9%)
Randomized, No. (%)	31 (57.4%)
Blinding, No. (%)	
Blinded	23 (42.6%)
Open Label	23 (42.6%)
Not Specified	8 (14.8%)
Comparator Type, No. (%)	
Active	14 (25.9%)
Sham	19 (35.2%)
Historical	2 (3.7%)
Pre-Post Comparison	8 (14.8%)
None	11 (20.4%)
Centers	
Multicenter	41 (75.9%)
Single Center	3 (5.6%)
Not Specified	10 (18.5%)
Locations	
All US	10 (18.5%)
Some US	10 (18.5%)
No US	2 (3.7%)
Not Specified	32 (59.3%)

Table 4. Characteristics of Primary Effectivess Endpoints of Pivotal Studies Supporting US Food and Drug Administration Clearance of De Novo Classification Therapeutic Medical Devices Between 2011 and 2019

	Pivotal Premarket
	Effectiveness
	Endpoints
	$(n=60)^a$
Endpoint Type, No. (%)	<u> </u>
Clinical Endpoint	36 (60.0%)
Clinical Scale	17 (28.3%)
Surrogate Marker	7 (11.7%)
Median Duration of Longest	
Follow-Up (months) (IQR)	
Overall	1.0 (0.0 - 6.0)
Non-Implantable	1.0 (0.0 - 3.0)
Implantable	9.5 (3.5 - 12.0)
Primary Endpoint(s) Met	
Yes	40 (66.7%)
No	18 (30.0%)
Endpoint(s) Success not Evaluated	2 (3.3%)

Notes: FDA=Food and Drug Administration; IQR=Interquartile Range

^a Does not include 5 pivotal studies supporting 5 devices without a primary effectiveness

endpoint

Table 5. FDA Rationale for Clearance of De Novo Devices with one or more missed primary effectiveness endpoints in supporting pivotal studies

evice Name	FDA-Cleared Clinical Indication	Failed Primary Endpoint	Rationale Supporting FDA ^a Clearance
irulite Cold ore Machine	Reduce healing time for herpes simplex labialis lesions on or around the lips	Time to healing from cold sore onset	-Literature review of device and similar devices provided reasonable assurance of safety and effectiveness - Low risk profile of device
ymphony evice	Improve sleep quality for patients with primary Restless Legs Syndrome (RLS)	Mean change from baseline in International Restless Leg Syndrome total score to week 1, 2, 3, and 4 ^b	Improvements in sleep quality (secondary endpoint) Lower risk profile than treatment alternatives (i.e., pharmaceuticals)
efaly	Prophylactic treatment of episodic migraine in patients \geq 18 years	Decrease in monthly migraine days against sham device group	-Success of co-primary endpoint (difference in responder (having a 50% reduction in monthly migraines) rate in treatment group vs. sham group) -Non-statistically significant trend in endpoint improvement Lower risk profile than treatment alternatives (i.e., pharmaceuticals)
anza-Click	Temporary reduction of the swelling and itching caused by mosquito bites.	Percent of patients with 40% itch reduction vs sham group	-Success of co-primary endpoint -Availability of device and similar devices OUS -Low risk profile of device
ereve Sleep ystem	Reduce sleep latency to Stage 1 and Stage 2 sleep in patients with primary insomnia.	 Latency to persistent sleep vs sham group Sleep efficiency vs sham group 	 -Decreased time to Stage 1 and Stage 2 sleep (incidental finding during additional analysis) - Low risk profile of device
ensor Ionitored limentary estriction herapy SMART) evice	Aid in weight management in overweight to obese (body mass index between range 27-35 kg/m2)individuals the in conjunction with behavioral modification instruction.	40% of the treatment group participants will lose more that 5% of their total body weight compared to under 10% of control group patients	-Lack of weight gain in treatment group - Low risk profile of device
ammaCore on-invasive agus Nerve timulator	Acute treatment of pain associated with episodic cluster headache in adult patients.	Rate of responders in the treatment group vs the sham group. A responder is defined as having recorded a headache intensity of 0 or 1 on a 5 point scale 15 minutes post-treatment with device.	 Positive trend for missed primary endpoint Post-hoc analysis demonstrating clinically meaningful improvement of first headache attack. Low risk profile of device
kinPen recision ystem	Improve the appearance of facial acne scars in adults aged 22 years or older.	Grading of patient photographs at 1 and 6 months post treatment by two blinded dermatologists using the Clinician's Global Aesthetic Improvement Assessment	 Success of co-primary endpoint (improvement on Acne Scar Assessment scale at 6 months compared to baseline) Non-statistically significant trend in endpoint improvement Lower risk profile than treatment alternatives

ermaPACE ystem	Treatment of chronic, full- thickness diabetic foot ulcers in conjunction with standard diabetic ulcer care.	Complete closure of target ulcer at 12 weeks ^b	 Post-hoc analysis demonstrating clinically meaningful benefit at 24 weeks Low risk profile of device
entinel erebral rotection ystem	Embolic protection device to capture and remove thrombus/debris while performing transcatheter aortic valve replacement procedures.	Comparison between treatment and control group patients of total new lesion volume in protected territories at 2 to 7 days post procedure assessed by diffusion weighted MRI	 Success of one of two criterion of primary effectiveness endpoint (30% reduction in 2-7 day lesion volume on diffusion-weighted MRI) Low risk profile of device per FDA
luminOss one tabilization ystem	Treatment of impending and actual pathological fractures in skeletally mature patients of the humerus, radius, and ulna, from metastatic bone disease.	Mean improvement in Visual Analog Scale pain score over 90 days of greater than 80% of historical reference	-Co-primary endpoint success -Positive trend for missed primary endpoint
EM Scanner Jodel 200)	Adjunct to standard of care when assessing the heels and sacrum of patients who are at increased risk for pressure ulcers.	Specifity of 55% or greater	 Success of co-primary endpoint (met sensitivity cutoff for detecting pressure ulcers) Low risk profile of device
ala ONE	Transient relief of hand tremors in adults with essential tremor.	Significantly greater change in treatment vs sham group in TETRAS Archimededs spiral rating after stimulation compared to baseline	-Improved tremor control versus baseline (not prespecified endpoint) -Low risk profile of device
inovo	Treatment of stress urinary incontinence in adult females	Comparison of percentage of patients with at least 50% reducting in Provocative Pad Weight Test at 12 weeks between active control and treatment group	-Improved urinary incontinence control versus baseline (not prespecified endpoint) -Low risk profile of device
lenity	Aid in weight management in overweight and obese (body mass index of 25 - 40 kg/m ²) when used in conjunction with diet and exercise.	3% superiority margin of total body weight loss in the treatment group vs the sham group	-Success of co-primary endpoint and secondary endpoints -Similar adverse event rate to sham control

^aFDA denotes the US Food and Drug Administration


^bDevice was supported by two pivotal studies with the same missed primary effectiveness

endpoint

FIGURES

Figure 1. Sample Construction of Therapeutic Moderate-Risk De Novo Devices Cleared

Between 2011 and 2019



Caption. Sample construction of therapeutic moderate-risk De Novo devices cleared between

2011 and 2019